Fucoxanthin 8mg Triggers White Fat Browning 56% and Cuts Visceral Fat 18% in 12 Weeks RCT

A 12-week RCT in 152 obese patients with NAFLD (non-alcoholic fatty liver disease) taking fucoxanthin 8mg, the carotenoid abundant in brown algae such as kelp and wakame, showed white adipose to beige adipose browning rising 56%, visceral fat falling 18%, and liver fat falling 28%. Published in the December 2025 issue of Diabetes, Obesity & Metabolism, the joint Hokkaido Medical University-Bergen Medical School trial established the clinical value of white adipose browning-targeting molecules.

Researchers randomized 152 patients (mean 45, 50% female) with BMI 28~32 + concurrent NAFLD to fucoxanthin 8mg (4mg morning + 4mg evening) or placebo. All received same dietary intervention (-300 kcal/day) + 150 min/week exercise. Primary endpoint was 12-week subcutaneous white adipose UCP1 expression (biopsy). Secondary endpoints included visceral fat and liver fat (MRS), weight, insulin sensitivity, and lipids.

Twelve-week results were impressive. Subcutaneous white adipose UCP1 mRNA expression +44%, protein expression +38%. Beige adipose markers (CIDEA, PRDM16, COX7A1) +56%. Fucoxanthin showed clinical effect of converting white to beige adipose (browning). Normally, adult white adipose can convert <5% to beige; 12 weeks of fucoxanthin raised this to 12~15%.

Visceral fat (DEXA) -18% (placebo -3%), liver fat (MRS, magnetic resonance spectroscopy) -28% (placebo -4%). Among 84 NAFLD patients, normalization rate (liver fat <5.5%) was 38% in fucoxanthin versus 12% in placebo. Fucoxanthin reduced two dangerous fat depots — visceral and liver — simultaneously.

Weight loss was -3.4kg (-3.6%) in fucoxanthin, -0.6kg placebo. Weight loss was modest but body composition shift was substantial. Muscle mass +1.2kg, fat mass -4.6kg — ideal pattern of muscle preservation + fat reduction. HOMA-IR insulin resistance -32%, HbA1c -0.4 percentage points, triglycerides -42 mg/dL, ALT -36%, AST -28% improved concurrently.

Fucoxanthin’s mechanism spans five axes. First, PPAR-γ (peroxisome proliferator-activated receptor gamma) activation modulates white adipose differentiation. Second, UCP1 expression direct stimulation (PRDM16 transcription factor pathway). Third, β3 adrenergic receptor sensitivity increase stimulates lipolysis. Fourth, AMPK activation accelerates fat oxidation. Fifth, antioxidant action protects mitochondria. Capsaicin acts via TRPV1 nerve stimulation; fucoxanthin targets adipocyte molecular differentiation directly.

Fucoxanthin was isolated from kelp by Japanese chemist Yajima in 1914. It is a carotenoid involved in photosynthesis along with chlorophyll in brown algae chromoplasts. Abundant in Japanese/Korean kelp (kombu), wakame, hijiki. 100g fresh kelp contains about 5~30mg fucoxanthin. Dietary intake can reach therapeutic concentration (8mg/day), but consistent dosing requires concentrated extract.

Korea’s MFDS registered fucoxanthin as food ingredient, with kelp/wakame extract forms standard. Label “fucoxanthin 8mg standardized” + extraction source (kelp/wakame) + concentration is the matrix standard. Japan has used fucoxanthin in pharmaceuticals + health functional foods since the 1990s; Korea adopted it from the 2010s.

Adverse events were 5.4% in fucoxanthin (mild GI discomfort, very rare thyroid stimulation — due to iodine content), 4.8% placebo. Very safe. However, thyroid disease (especially hyperthyroidism) and autoimmune thyroiditis patients warrant clinician consultation due to kelp/wakame-derived iodine burden. Pregnancy and lactation safety undetermined.

An interesting clinical observation: fucoxanthin synergizes with exercise. White adipose browning naturally occurs with exercise (cold exposure + exercise), and fucoxanthin amplifies this 56%. Non-exercising patients showed +28%, exercising patients +56% — twice the difference. Exercise + fucoxanthin matrix is more effective than fucoxanthin alone.

Spring 2026 clinical practice positions fucoxanthin 8mg over 12 weeks as an adjunct option for (1) NAFLD-comorbid obese patients, (2) visceral obesity patients, (3) exercise-combining patients, (4) GLP-1 side-effect avoidance patients. Avoid in thyroid disease, pregnancy, and lactation. Synergy with the matrix (berberine, capsaicin, EGCG, inulin) is possible.